Abstract:Glycosylation, the process of adding glycans (i.e., sugars) to proteins, is the most abundant post-translational modification. N-glycosylation is the most common form of glycosylation, and the N-glycan moieties play key roles in regulating protein functions and many other biological processes. Thus, identification and quantification of N-glycome (complete repertoire of all N-glycans in a sample) may provide new sources of biomarkers and shed light on health and disease. To date, little is known about the role of altered N-glycome in Alzheimer’s Disease and Alzheimer’s Disease-related Dementias (AD/ADRD). The current study included 45 older adults who had no cognitive impairment (NCI) at baseline, followed and examined annually, and underwent brain autopsy after death. During about 12-year follow-up, 15 developed mild cognitive impairment (MCI), 15 developed AD, and 15 remained NCI. Relative abundances of N-glycans in serum at 2 time points (baseline and proximate to death, ∼12.3 years apart) and postmortem brain tissue (dorsolateral prefrontal cortex) were quantified using MALDI-TOF-MS. Regression models were used to test the associations of N-glycans with AD/ADRD phenotypes. We detected 71 serum and 141 brain N-glycans, of which 46 were in common. Most serum N-glycans had mean fold changes less than one between baseline and proximate to death. The cross-tissue N-glycan correlations were weak. Baseline serum N-glycans were more strongly associated with AD/ADRD compared to change in serum N-glycans over time and brain N-glycans. The N-glycan associations were observed in both AD and non-AD neuropathologies. To our knowledge, this is the first comprehensive glycomic analysis in both blood and brain in relation to AD pathology. Our results suggest that altered N-glycans may serve as mechanistic biomarkers for early diagnosis and progression of AD/ADRD.

N-glycan Profiles As Tools in Diagnosis of Hepatocellular Carcinoma and Prediction of Healthy Human Ageing

N-Glycan profiling in the study of human aging

Serum N-glycan Profiling As a Diagnostic Biomarker for the Identification of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Alteration of Liver N-glycome in Patients with Hepatocellular Carcinoma

Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach.

N-glycomic biomarkers of biological aging and longevity: A link with inflammaging

Human serum N-glycan profiles are age and sex dependent.

Identification of N-glycosylation in Hepatocellular Carcinoma Patients' Serum with a Comparative Proteomic Approach.

N-glycan, a biomarker in current cancer diagnosis

Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis

Altered serum<i>N</i>-glycomics in chronic hepatitis B patients

A Rapidly Aging World in the 21st Century: Hopes from Glycomics and Unraveling the Biomarkers of Aging with the Sugar Code

Human Brain and Blood N-Glycome Profiling in Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias

Serum-based Comprehensive N-Glycans Profiling Analysis in Different Gastric Disease Stages by Porous Graphitic Carbon Liquid Chromatography-Mass Spectrometry Associated with Potential Marker Discovery.

Expression of N-glycome in Sera of Patients with Hepatocellular Carcinoma

Comprehensive N-Glycome Profiling of Cells and Tissues for Breast Cancer Diagnosis.

Glycoproteomics investigation of human hepatocellular carcinoma cell lines

Profiling of isomer-specific IgG <i>N</i>-glycosylation in cohort of Chinese colorectal cancer patients

Altered Serum N-Glycomics In Chronic Hepatitis B Patients

Novel Three-Dimensional Hierarchical Porous Carbon Probe for the Discovery of N-Glycan Biomarkers and Early Hepatocellular Carcinoma Detection.

Glycomics as prognostic biomarkers of hepatocellular carcinoma: A systematic review